
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is attractive fundamentally because it combines FDA-cleared connected hardware, evidence-backed clinical programs, and AI trained on 13B+ proprietary data points, creating a hard-to-replicate platform with stronger personalization, engagement, and outcomes than software-only peers. Its commercial base is broad and still expanding, with 180+ enterprise customers, 25% from Fortune 500 companies, access to more than 175M lives, and 85 new clients added in 2025, while over 80% of ARR already comes from multi-condition sales. Despite near-term revenue pressure from the bio-pharma transition and a large legacy account roll-off, the business has ~$13.1M of contracted and late-stage ARR, 62% gross margin in 2Q:26, 90% client retention, and management expects AI and new wins to support improving revenue and cash flow.
Bears say
DarioHealth is facing a fundamentally difficult setup marked by intense competition in crowded employer and payer channels, where it must compete against both point solutions and shifting benefit budgets, limiting visibility into sustained share gains. Its latest results underscore the strain: 2Q revenue of $5.2M missed estimates, adjusted EBITDA loss was ($5.3M), and management’s lack of formal guidance, alongside revised 2026/2027 revenue and EBITDA estimates, signals an uncertain path to profitability. That uncertainty is compounded by roughly $31M of debt versus about $7M of cash at 2Q:26, continued execution risk in converting $13M of new contracted ARR, and the possibility that weak demand, churn, or further dilutive financing could pressure the stock.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About DarioHealth (DRIO) Forecast
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares